Influvac

Influenza virus vaccine, the active ingredient in Influvac, is a vaccine presented as a lyophilized powder for suspension for injection for intramuscular, subcutaneous use. It is used to prevent influenza infection caused by influenza A and B viruses in individuals at risk, such as adults and children.

GNH USA supplies Influvac as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across global markets.

Influvac is a vaccine that targets influenza viruses to provide prophylactic protection. - Seasonal influenza: reduces the risk of illness caused by circulating influenza A and B strains during flu season. - Influenza A infection: prevents disease caused by influenza A viruses included in the vaccine composition. - Influenza B infection: prevents disease caused by influenza B viruses included in the vaccine composition.

Common and serious adverse reactions have been reported following administration of Influvac.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness and swelling: localized erythema and edema. - Fever: low-grade temperature elevation within 24‑48 hours. - Headache: transient mild headache. - Myalgia: muscle aches lasting up to a few days. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder potentially triggered post‑vaccination. - Seizures: infrequent occurrence, especially in children with fever. - High fever: temperature above 39 °C persisting more than 48 hours. - Severe allergic reaction: urticaria, angioedema, or respiratory distress. - Thrombocytopenia: rare drop in platelet count.

Before administering Influvac, consider the following precautions and warnings. - Allergy assessment: verify no known hypersensitivity to egg proteins or any vaccine component. - Prior severe reaction: avoid in individuals who experienced anaphylaxis after a previous influenza vaccine. - Immunocompromised patients: vaccine may elicit a reduced immune response; assess benefit‑risk. - Age restriction: not indicated for children younger than 6 months. - Pregnancy and lactation: limited safety data; use only if potential benefit justifies risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Influvac may interact with certain medical products or therapies; observe the following.

Major Interactions (Avoid): - Live attenuated vaccines: avoid simultaneous administration to prevent interference. - Immunoglobulin therapy: concurrent use may diminish vaccine‑induced immunity. - Antiviral agents (e.g., oseltamivir) taken within 48 hours: may reduce antibody response.

Moderate Interactions (Monitor Closely): - High‑dose corticosteroids: may lower immunogenicity, monitor protective effect. - Febrile illness at vaccination: postpone until recovery to reduce adverse events. - Co‑administration of other inactivated vaccines: generally safe but observe for additive local reactions.